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Tumor vaccines are an important asset in the field of cancer immunotherapy. Whether
prophylactic or therapeutic, these vaccines aim to enhance the T cell-mediated
anti-tumor immune response that is orchestrated by dendritic cells. Although promising
preclinical and early-stage clinical results have been obtained, large-scale clinical
implementation of cancer vaccination is stagnating due to poor clinical response. The
challenges of clinical efficacy of tumor vaccines can bemainly attributed to tumor induced
immunosuppression and poor immunogenicity of the chosen tumor antigens. Recently,
intratumor heterogeneity and the relation with tumor-specific neoantigen clonality were
put in the equation.In this perspective we provide an overview of recent studies showing
how personalized tumor vaccines containing multiple neoantigens can broaden and
enhance the anti-tumor immune response. Furthermore, we summarize advances in
the understanding of the intratumor mutational landscape containing different tumor cell
subclones and the temporal and spatial diversity of neoantigen presentation and burden,
and the relation between these factors with respect to tumor immunogenicity. Together,
the presented knowledge calls for the investment in the characterization of neoantigens
in the context of intratumor heterogeneity to improve clinical efficacy of personalized
tumor vaccines.
Keywords: tumor vaccines, personalized vaccines, neoantigens, intratumor heterogeneity, multiplex neoantigen
vaccines
INTRODUCTION–A SHORT HISTORY OF TUMOR VACCINES
The beginnings of immunotherapy date back to the late Nineteenth century. In 1891, the
American bone surgeon William B. Coley started to treat cancer patients with bacterial
injections with the rationale to stimulate the immune system and thereby enhance tumor
cell killing. With varying success “Coley’s Toxins” were accepted as treatment for inoperable
bone cancers but could never fully be clinically established (1). In 1909, Paul Ehrlich
established the concept of protective vaccinations of mice by transplanting them with
foreign tumors. He described that in 50–100% of vaccinated mice an acquired tumor-
directed immunity could be observed (2). The genetic basis of this type of rejection was
discovered in 1914 by Clarence Little (3), and later linked to histocompatibility antigens
on transplanted tumors by Gorer et al. (4). In line with these findings, Foley (5) and
Prehn et al. (6) investigated the mechanism of protection in mice against carcinogen-induced
sarcomas after rechallenge with the same tumor, thereby formulating the rational of using
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tumor tissue as a vaccine. In the following years more pieces of
the immunological puzzle were solved finally culminating in the
concept of immunological surveillance, formulated by Burnet in
1970, further justifying the use of cancer vaccines (7).
Nowadays, it is well-established that tumor vaccines can
effectively mount an anti-tumor immune response. These
vaccines can be comprised of whole tumor lysates, recombinant
tumor proteins, tumor antigen derived epitope peptides, or
antigen encoding mRNA and DNA (8). Once injected, dendritic
cells (DCs) play a crucial role by taking up the vaccine and
presenting the vaccine-derived tumor epitope in the context of
major histocompatibility class (MHC) I or II complexes to CD8+
or CD4+ T cells, respectively (9, 10). In turn, ideally tumor
specific CD8+ T cells will be activated, proliferate and infiltrate
into the tumor to exert cytotoxic functions. CD4+ T cells are
skewed toward T helper cell subsets and support the anti-tumor
immune response by the release of cytokines (11, 12) or tumor
cell killing (13).
Despite promising results obtained in 1995 with a DC vaccine
pulsed ex vivo with the melanoma tumor antigen 1 (MAGE-1)
(14, 15), it was not until 2010 before the first DC-based vaccine
Sipuleucel-T was approved by the Food andDrugAdministration
(FDA). This revitalized the tumor vaccine field resulting in the
initiation of clinical trials to test new formulations and delivery
methods of tumor vaccines across multiple types of cancers.
Especially, recent developments in the understanding of the
nature of tumor antigens have attributed to the improvement of
tumor vaccines. Together with new insights into the mutational
landscape of tumors and their evolution these findings are
instrumental for the rise of novel, multiplex and personalized
tumor vaccines.
THE IMPORTANCE OF
ANTIGEN-SPECIFICITY FOR
TUMOR VACCINES
Since Edward Tyzzer coined the term “somatic mutation” in
1916 for describing “modifications of the somatic tissue” that
determine foreignness and antigenicity of a transplanted tumor,
it took until 1991 to discover the first tumor antigen MAGE-
1(16, 17). MAGE-1 was shown to be expressed on patient-
derived melanoma cells and in immune privileged sites, such as
testis, hence the name cancer/testis antigen (CTA), and therefore
qualified as a good target for immunotherapy (17). Although
CTAs are specific targets on tumor cells and therefore classify
as candidates for tumor vaccines, their expression is limited
to a small number of tumors and patients (18). In contrast to
cancer/testis antigens, tumor-associated antigens (TAAs), such
as gp100, tyrosinase or EGFR, are overexpressed on tumor
cells and are shared in a bigger patient population (19). Their
concurrent expression on healthy cells however, will result in
a weaker antigen-specific immune response, due to negative
selection as a consequence of central tolerance. Furthermore,
DCs and regulatory T cells will dampen the immune response by
inducing peripheral tolerance and inhibiting effector T cells (20).
Together with the potential of inducing auto-immune reactions,
these features underline that TAAs are not ideal candidates
for effective tumor vaccination and that therapy targets are
preferably expressed exclusively on tumor cells.
In 1994, the first report of such tumor-specific antigen
(TSA) was published, being a mutated version of the membrane
protein Connexin-37 in Lewis lung carcinoma (21). In the
following years the rise of next-generation sequencing techniques
led to the discovery of more TSAs or so called neoantigens.
Neoantigens are seen as highly specific tumor antigens that arise
due to somatic mutations exclusively in tumor cells while being
absent in healthy cells [for extensive reviews about neoantigens
see (22, 23)]. Except of mutations in driver genes, such as
isocitrate dehydrogenase 1 (IDH1)(24) or KRAS(25) and in a
rare form of hereditary colon cancer, called Lynch syndrome(26),
neoantigens are not shared between individual patients and can
have differential expression in tumor clones within one patient,
as will be discussed later. Moreover, the load of neoantigens has
been positively correlated with the presence of tumor-infiltrating,
neoantigen-specific T cells and a good prognosis for checkpoint
inhibitor therapy and survival across different types of cancers
(27, 28). In turn researchers have made use of sequencing and
peptide-based assays combined with computational filtering and
prediction algorithms for the selection of candidate neoantigens
to design the first generation of personalized tumor vaccines (29,
30). An example of such, is a point mutation in the gene encoding
IDH1, which is shared by about 70% of diffuse grade II and III
glioma patients, as mentioned above. Using the mutant IDH1
as synthetic long peptide vaccine, Schumacher et al. observed
reduced tumor growth in vaccinated mice carrying tumors with
the IDH1 point mutation compared to mice carrying IDH1 WT
tumors (Table 1) (24).
FROM SINGLE TO MULTIPLEX
PERSONALIZED NEOANTIGEN VACCINES
The IDH1 synthetic long peptide is an example of a rationally
designed neoantigen vaccine based on a tumor-specific point
mutation shared by a large patient population with a mildly
immunogenic tumor. For more immunogenic tumors with
higher mutational load such as melanoma, high throughput
genome screens are needed. One of the first studies applying
this strategy used massive parallel sequencing of mouse tumor
and healthy tissue combined with RNA expression profiling
and immunogenicity tests to obtain potential neoantigen
sequences for vaccination purposes. Eventually, vaccinations
were performed with two to five neoantigens in the form of
synthetic long peptides or mRNA. These led to significant delay
of tumor growth and protection of mice in a prophylactic (29) or
therapeutic setting (29, 30). Predicted mutations for the B16F10
melanoma, CT-26 colon cancer or 4T1 mammary carcinoma
models by Castle and Kreiter et al. were subsequently used
and extended to generate neoantigen vaccines targeting more
than one epitope simultaneously, and delivered as synthetic
long peptide (43), mRNA (41), by carrier molecules such as
nanoparticles (31, 34, 36, 39), nanodiscs (38, 45) or other
modalities (33, 35, 46) (Table 1). In addition to this, in
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TABLE 1 | Summary of neoantigen vaccine studies ordered by the amount of neoepitopes that are incorporated in the vaccine.
Tumor type Organism Neoantigen identification
(origin, method)
Neoantigen
prediction
Vaccine format Amount of
neoantigens used for
vaccination
Year Publication
Melanoma,
B16F10
Mouse (29)
Mass spectronomy
- PLGA capturing
endogenous
neoantigen containing
proteins
n.m. 2017 (31)
Colon cancer CT26,
TC-1, melanoma
B16F10
Mouse (29) - SLP in
polyethyleneimine
mesoporous silica
microrods
n.m. 2018 (32)
Colon cancer
MC-38, TC-1
Mouse (33) - Ferritin nanoparticle
neoantigen conjugates
1 (TC-1)
3 (MC-38)
2019 (34)
Sarcoma,
A2.DR1
Mouse (Most frequent point
mutation in glioma)
- SLP 1 2014 (24)
Colon cancer CT26,
TC-1, melanoma
Mouse (29) - RNA lipoplex 1 2016 (35)
Colon cancer,
MC-38
Mouse (33) - RNA-DNA
nanostructures
1 2018 (36)
Sarcoma,
d42m1-T3 and F244
Mouse Complement DNA capture
sequencing,
3x MHCI epitope binding,
processing by
immunoproteasome
SLP 2 2014 (37)
Melanoma,
B16F10
Mouse B16F10 cells,
DNA/RNA sequencing
Expression, Location,
mutation type,
immunogenicity
SLP 2 2012 (29)
Melanoma B16F10,
colon cancer MC-38
Mouse (29, 33) - RNA nanodisc 2 2016 (38)
Colon cancer
MC38
Mouse Whole exon and RNA
sequencing, Mass
spectronomy
netMHC binding prediction,
solvent exposure in MHC
SLP 3 2014 (33)
Melanoma, colon
cancer, HPV E6/E7
Mouse (29) - PC7A nanoparticle 3 2017 (39)
Melanoma
B16F10
Mouse Exome/RNA sequencing MHCII Class binding mRNA 5 2015 (30)
Melanoma Human Resected tumor, Exome
sequencing
Binding to HLA-A, cDNA
expression
SLP 7 2015 (40)
Stage III/IV
Melanoma
Human Tumor biopsy,
Exome and RNA
sequencing
Binding affinity to HLA class
II and expression of
mutation encoding RNA,
and HLA class I binding
mRNA 10 2017 (41)
Lewis lung
carcinoma, TC-1,
ovarian cancer ID8
Mouse Cell lines and lysed tumor,
Whole exome and RNA
sequencing
Binding affinity to HLA class
I and II, proteasomal
processing
Plasmid DNA 12 2019 (42)
Melanoma
Stage IIIB/C
Stage IVM1a/b
Human Whole exon sequencing and
RNA sequencing
Binding to HLA-A and -B SLP 20 2017 (43)
Glioblastoma Human
Phase I/Ib
Whole exon sequencing and
RNA sequencing
Binding to HLA-A and -B SLP 20 2019 (44)
n.m, not mentioned.
pre-clinical mouse studies, the concurrent use of checkpoint
inhibitors programmed cell death-1 (PD-1) or cytotoxic T-
lymphocyte-associated protein-4 (CTLA-4) at the time of
vaccination worked synergistically and enhanced the treatment
outcome (31, 34, 39, 45).
In clinical studies of late stage melanoma patients, multiplex
personalized neoantigen vaccines have achieved significant
results in clinical studies of late stagemelanoma patients, as nicely
summarized by Hellmann and Snyder (47). Recently, a similar
approach has been presented for phase Ib glioblastoma patients.
These patients received personalized neoantigen vaccines,
covering 20 neoepitopes in the form of long peptides, based on
mutational profiling and RNA expression analysis of surgically
resected tumors. Although all patients died due to progressive
disease, neoantigen-specific CD8+ and CD4+ T cells could be
observed which were able to infiltrate into the tumor (44).
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Finally, also DNA has been used as a delivery vector for encoding
neoantigen vaccines. Duperret et al. used a combination of
intramuscular injection and electroporation of plasmids with
strings of up to twelve 9-mer neoepitopes, derived from
lung carcinoma or ovarian cancer. Neoantigen-specific immune
response were predominantly guided by CD8+ T cells and
resulted in a delay of tumor growth and increased survival in
prophylactically or therapeutically vaccinated mice (42).
Concurrently, a general trend that can be observed in recent
studies is an increase in neoepitope incorporation into tumor
vaccines (Table 1). This is mainly the result of the increasing
improvements of next-generation sequencing and computational
tools for prediction of neoantigens, providing a more detailed
view on the mutational landscape of tumors.
Argumentation supporting multiplex neoantigen vaccines can
be found in a more fundamental aspect of tumor evolution which
has been elucidated, especially within the last 10 years. It relates
to the understanding of the identity of individual tumor cells
within specific regions in the tumor mass. Although it is well-
known that tumors are heterogeneous, comprised of different cell
types, such as immune cells and stromal cells, more knowledge
had to be gained at the single cell- and genotypic- level of
malignant cells. As such, it was elucidated that a certain degree
of tumor cell evolution takes place within one tumor leading
to the formation of subclones separated not only spatially, but
also by mutational patterns (48–52). The latest key findings on
the deciphering of intratumor heterogeneity (ITH), its relation
to neoantigen expression and its effect on the immune system
and immunotherapy present an essential milestone toward the
next generation of multiplex personalized neoantigen vaccines
and offer an outlook on the challenges we face in the future.
INTRATUMOR HETEROGENEITY
CHALLENGING MULTIPLEX
PERSONALIZED NEOANTIGEN VACCINES
The concept of ITH was first introduced in the 1970’s
by Prehn et al. who investigated the immunogenicity of
methylcholanthrene-induced murine sarcomas. Paired cancer
cell subclones from different regions of a primary tumor showed
differential induction of immune responses after transplantation
into recipient mice. These differences were thought to be
caused by distinct antigenicity and immunogenicity of subclones,
hence a heterogeneous distribution within one tumor (53). In
the following years other groups extended this knowledge by
delineating the types of immune responses toward heterogeneous
tumors based on subclonal expression of tumor antigens (54).
The first human study to investigate the extent of ITH
within one tumor mass was performed in 2012 by Gerlinger
et al. (48). In this study, several biopsies from a patient-derived
primary renal-cell carcinoma were analyzed by whole-exome
sequencing and aligned to healthy tissue. Next to several shared
mutations between different subclones, ca. 23% of the mutations
were only found in specific regions of the tumor. Strikingly, a
single biopsy of that same tumor only covered around 55% of
the total mutational diversity, underlining the need for multi-
region sampling. Tracing the order of mutations in different
subclones revealed that they develop in a branching fashion
from the primary tumor clone, harboring the driver mutation,
rather than in a linear model. Remarkably, these differentially
branched subclones harbored different mutations in the same
gene which suggests a mode of convergent evolution (48). These
findings emphasize the importance of multi-region sampling of
tumor samples, as it can explain the mutational ancestry of a
tumor and thereby aid in the selection of neoantigens for tumor
vaccination, which ideally target mutations from the trunk of the
phylogenetic tree.
Besides being able to reconstruct the mutational history, it
is also important to correlate this to the developmental stage of
the tumor as shown by De Bruin et al. (49). In patients with
non-small cell lung cancer (NSCLC) mutational events in the
primary tumor coupled to known driver genes could be identified
in the context of tobacco-induced carcinogenesis, bearing typical
C>T transitions in early development. Mutations in driver
genes were also observed in subclones of later development,
however these clones also acquired other somatic mutations
indicative of a branched evolution and supporting the idea
of ITH in NSCLC. Knowing that these tumors carry driver
mutations in late stage development, in different regions of the
tumor, emphasizes the benefit of multi-dimensional sampling
and sequencing for developing tumor vaccines that target these
driver mutations (49). Importantly, in this study <5% of the
tumor tissue could be analyzed, which probably underestimates
the extend of observed ITH.
As growing evidence suggests that diverse sets of mutations
occur in subclones in distinct regions of one tumor, McGranahan
et al. asked to what extent these mutations translate into
neoantigens and how neoantigen ITH (NITH) relates to the anti-
tumor immune response (50). Analysis of neoantigen burden
and NITH in single biopsies from roughly 200 cases of different
types of lung cancers was performed. Using whole-genome
and -exome sequencing and bioinformatic processing revealed
that a high clonal neoantigen burden (upper quartile of total
neoantigen burden) combined with a low NITH (smaller than
1%) correlates with a longer survival in lung adenocarcinoma
patients. In contrast, a lower neoantigen clonality (higher NITH)
characterized the tumor as more heterogeneous which correlates
with a shorter survival (Figure 1A). More homogeneous
tumors showed genetic signatures of an inflamed or hot
tumor microenvironment with upregulated genes for antigen
presentation, T cell migration and effector functions next to
inhibitory molecules such as programmed death receptor ligand
1 (PD-L1). As a consequence to this environment, active
interferon γ, granzyme B, H and A producing, PD-L1 and
lymphocyte activation gene 3 (LAG-3) expressing CD8+ T
cells specific to clonal neoantigens could be identified within
the tumors by MHC multimer staining and flowcytometric
analysis. Whether earlier in the development of the tumor it
was more heterogeneous, homogenized by initial neoantigen
specific T cell infiltration, leading to attraction of more
immune cells and an inflamed tumor microenvironment, is
however difficult to investigate due to the lack of samples
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FIGURE 1 | (A) The impact of low and high intratumor heterogeneity (ITH) on clonal ancestry, neoantigen clonality and T cell responses. Tumors that show low ITH
(left panel) typically have few branching mutations as indicated in the clonal ancestry panel. In turn, more cells in the tumor harbor the same mutation, which is
potentially translated and presented on the cell as a neoantigen. The overall neoantigen clonality (the number of cells that express one specific neoantigen, indicated
by black-gray triangle) is therefore higher, leading to a lower neoantigen ITH and subsequently in a better neoantigen-specific T cell response. Tumors that have a high
ITH in contrast (right panel), show more branching mutations leading to an increased amount of neoantigens expressed. Having more subclones with specific
neoantigens however decreased the neoantigen clonality and increases neoantigen ITH. This will result in a weaker neoantigen-specific T cell response. (B) Workflow
(Continued)
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FIGURE 1 | for the designing of next generation multiplex neoantigen vaccines addressing ITH (1–6). (1) Ideally, the generation of multiplex neoantigen vaccines starts
with multi-region tumor sampling by preferentially, non-invasive techniques. (2) Acquired data will then be analyzed by whole-genome/-exome sequencing for
detection of mutations and RNA expression analysis to infer whether these mutations are located within transcribed regions. (3, 4) From this the subclonal ancestry
can be inferred to determine the overall neoantigen clonality and ITH. (5) By mapping found neoantigens to subclones in the tumor and the ancestral tree, target
neoantigen can be chosen that are located in the trunk and/or branching regions. (6) Finally, state-off the art prediction algorithms can supplement the aforementioned
workflow to cross-validate found neoantigen vaccine candidates that will be incorporated in the final vaccine or vaccine carrier. Panels I-III depict the in vivo processing
of multiplex neoantigen vaccines leading to a multi-angled anti-tumor T cell response. (I) After injection of multiplex neoantigen vaccines dendritic cells (DCs) will take
up and process the vaccine and present antigenic epitopes on the cell surface complexed with MHC molecules. (II) Subsequently, T cells will interact with DCs via T
cell receptor-MHC interaction and co-stimulatory molecules and will be further activated under the influence of cytokines. (III) Effector T cells will finally perform
cytotoxic effector functions targeting several subclones in the heterogenous tumor.
from these earlier developmental stages of the tumor. The
observation that these tumors harbored an inflamed, PD-
1/L1 expressing microenvironment was the rationale to inhibit
PD-1 by checkpoint immunotherapy, which resulted in a
clinical benefit for patients with these inflamed tumors.
In the same study, similar results have been obtained in
a melanoma patient cohort treated with PD-1 checkpoint
immunotherapy, where patients with high clonal neoantigen
burden and low NITH showed prolonged survival (50). Another
example supporting combination of multiplex neoantigen
vaccines and checkpoint immunotherapy is provided by two
clinical studies of Ott et al. (43) and Sahin et al. (41). In
these studies, stage III-IV melanoma patients are initially
treated with RNA -or long peptide-based multiplex neoantigen
vaccines (Table 1). While most of the patients experienced
progression free survival as consequence of neoantigen specific
T cell infiltration into the tumor, some showed recurrent
disease during multiplex neoantigen vaccination. In these cases,
combinatorial treatment with PD-1 blocking antibodies was able
to remove tumor mediated immunosuppression and unleash
neoantigen-specific T cells that were generated by the vaccine
(41, 43).
The discovery that checkpoint immunotherapy results
in prolonged survival once neoantigen-specific cytotoxic T
cells have infiltrated these tumors, presents a rationale to
combine multiplex neoantigen vaccination with checkpoint
immunotherapy for tumors with low NITH.
Based on the aforementioned clinical examples a sequential
treatment with first multiplex neoantigen vaccines and then,
if needed, checkpoint therapy can be suggested to reduce
the amount of patients that are unnecessarily treated with
checkpoint inhibitors.
As already briefly touched upon above, to what extent
neoantigen-specific immune responses shape the heterogeneity
of a tumor throughout tumorigenesis by targeting dominant
subclones and whether this can lead to tumor escape of
untargeted clones remains to be determined.
By applying multi-color barcoding of male Eµ-myc
lymphoma cells, Milo et al. studied tumorigenesis and subclonal
distribution in a metastatic mouse model (51). When injected
in male recipient mice, the differentially colored tumor cells
seeded in different proximal niches, ultimately resulting in
equally heterogeneous tumors, demonstrating equal survival
and outgrowth of the injected barcoded tumor cells. When
these cells were injected in female recipient mice, homogeneous
tumors with one or two dominant colors established in a CD8+
T cell dependent manner. Part of the explanation for this
observation can be found in the expression of Y-chromosome
derived H-Y antigens, which induced an antigen-specific T
cell-mediated immune response. However, the injected mix of
color coded tumor cells contained up to 25% non-immunogenic
cells due to a loss of the Y-chromosome, suggesting additional
clonal reduction as a result of epitope spreading, ultimately
resulting in homogeneous Y chromosome deficient tumors.
Additionally, whole genome exome-sequencing was applied
in this system to infer whether the neoantigen repertoire is
narrowed as a consequence of the anti-tumor immune response.
In line with the reduction in color-coded subclones in female
recipients also NITH was reduced, underlining that the immune
system actively shapes subclone diversity and NITH during
immunosurveillance, resulting in the evolution of one or few
escaping subclones (51).
In a first attempt to study the contribution of neoantigen
immunogenicity in the emergence of dominant tumor cell
subclones Gejman et al. developed an artificial antigen-
presentation system allowing the construction of heterogeneous
tumors, expressing up to five thousand defined artificial MHCI
neoepitopes (52). Looking at the clearance of immunogenic
subclones within a largely heterogeneous tumor in mice,
it was revealed that the immune system was incapable of
elimintating small clonal fractions of immunogenic subclones. It
appeared that the percentage of neoepitope subclonal tumor cell
representation is an important determinant for its clearance. This
critical subclonal percentage seemed to differ between individual
neoepitopes (52). The exact mechanisms behind the persistence
of tumor cell subclones, although partly assigned to absence of
antigenicity or clonality, remains to be elucidated in more detail.
These two studies emphasize the need for controlled systems
to investigate the dynamic process of immunosurveillance in
the context of heterogeneous tumors with known mutations
or neoepitopes to determine how the immune system can be
used to reduce subclone diversity and ultimately enable the total
clearance of the tumor.
CONCLUSION
The discovery of neoantigens and their use as tumor vaccines
generated a lot of momentum in the tumor vaccination field.
Personalized neoantigen vaccines hold promise in generating
specific anti-tumor immune responses and durable survival
benefits as emphasized by several pre-clinical and clinical studies.
Especially in the last 2 years, vaccines comprising of not one,
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but several neoepitopes, so called multiplex neoantigen vaccines,
have been developed in order to successfully increase the breadth
of the anti-tumor immune response.
A rationale that supports this development is obtained from
recent insights into the dynamic evolution of tumors. This
evolution is characterized by the time-dependent acquisition
of region-specific mutations and leads to the emergence of
genetically distinct tumor cell subclones within one tumor,
as shown by multi-region sampling and massive parallel
sequencing. These subclone-specific mutations define the
neoantigen clonality, burden and therefore the total NITH, which
in turn affects the potency of immunosurveillance. Tumors with
a high neoantigen clonality and a low NITH show a better tumor
clearance. More heterogeneous tumors with lower neoantigen
clonality are more difficult to eradicate (Figure 1A). Depending
on this balance between neoantigen clonality and NITH, T cells
are able to reduce the diversity of subclones within a tumor
and thereby actively shape the ITH. Two important factors
which influence the efficacy with which T cells can clear a
specific subclone within a heterogeneous tumor seem to be
the antigen itself and the percentage of tumor cells expressing
this antigen. The exact underlying mechanism has still to be
uncovered and can possibly aid us in choosing the right antigens
for preventing the emergence of dominant subclones. In the
meanwhile, targeting more neoantigens by multiplex neoantigen
vaccines is a feasible approach to induce a specific immune
response against several subclones in the tumor and thereby
address ITH.
FUTURE PERSPECTIVES
Although current studies with multiplex neoantigen vaccines
(Table 1) seem to tackle ITH by including more neoepitopes,
they are limited by the snapshot of the mutanome acquired by
a single biopsy. We believe that the lack of multi-dimensional
tumor information in these neoantigen vaccine studies impairs
the power of inducing a multi-angled immune response against
all the subclones in a tumor. Challenging pre-clinical longitudinal
studies of tumorigenesis are needed, taking into account samples
from different locations in the tumor at different time points,
both before and after treatment. These studies would gain insight
in the dynamics of tumor evolution in the context of multiplex
neoantigen vaccination. Ultimately, this knowledge could be
integrated into the process of designing the next generation
of multiplex neoantigen vaccines. Currently, driving neoepitope
selection criteria are predicted MHCI binding as well as T
cell receptor affinities. We propose a workflow (Figure 1B)
starting with the multi-regional NITH acquisition of available
biopsies, to obtain multi-dimensional tumor biopsy information,
from which dominant clonal neoepitope vaccine candidates
could potentially be extrapolated. Attractive, less invasive and
practically more feasible alternatives, such as circulating tumor
DNA or tumor exosome DNA sequencing, deserve special
attention. Varying reports exist about the success of these two
techniques in comprehending ITH, which underlines the need
for further development of these tools (55–57). Next-generation
sequencing and bioinformatic tools that have been developed
in the recent years (48, 58–62) will then be an essential asset
to acquire genomic sequence information of high, subclonal
resolution. With this information the clonal architecture
and mutational ancestry of subclones can be reconstructed.
Subsequently, neoantigen clonality and burden can be inferred
to predict total NITH and map neoantigens to the subclone
architecture of the tumor. This dynamic genomic blueprint
of the tumor will aid in determining optimal neoantigen
candidates for vaccination purposes and can be complemented
with bioinformatic prediction algorithms and novel tools to
assay T cell reactivity on a large scale (63). Current vaccine
production platforms as described earlier, can then facilitate the
efficient formulation and delivery of the vaccine to the patient
in vivo, where DCs will process vaccine content and activate
neoantigen specific T cells that will infiltrate and eradicate the
tumor (Figure 1B, p. 1–3).
We are convinced that the development of more refined
techniques to sample and predict the right neoantigens
for vaccination can address ITH, and will be essential to
fuel the progress that is currently made with regard to
time efficient formulation, design and delivery of multiplex
neoantigen vaccines [as extensively reviewed by others (64,
65)]. With these techniques in mind, we could create a more
detailed map of the neoantigen clonality in primary tumors
and metastasis to determine shared mutations within these
regions as shown earlier (48). Along this line, combining
multiplex neoantigen vaccines with TAA or CTA epitopes
could present a handle to increase the chances of epitope
spreading and sensitize the immune system for a priori
low abundant neoantigens. A full comprehension of tumor
evolution and neoantigen distribution will be the fundament
for counteracting the survival of the fittest tumor clone and
will pave the way for powerful next-generation multiplex
neoantigen vaccines.
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